Vascular Endothelial Growth Factor Inhibitor Therapy and Cardiovascular and Renal Damage in Renal Cell Carcinoma

E-ISSN： 1875-6212|16|2|190-196

ISSN： 1570-1611

Source： Current Vascular Pharmacology, Vol.16, Iss.2, 2018-01, pp. : 190-196

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Transforming growth factor β1 T29C gene polymorphism and hypertension: Relationship with cardiovascular and renal damage

By Argano Christiano Duro Giovanni Corrao Salvatore Di Chiara Tiziana Nuzzo Domenico Colomba Daniela Scaglione Rosario Licata Giuseppe

Blood Pressure, Vol. 17, Iss. 4, 2008-01 ,pp. : 220-226

Informa Healthcare

Access to resources Recommend Favorite

Bone marrow mononuclear cell therapy limits myocardial infarct size through vascular endothelial growth factor

By Hiasa Ken-ichi

Basic Research in Cardiology, Vol. 99, Iss. 3, 2004-05 ,pp. : 165-172

Springer Publishing Company

Access to resources Recommend Favorite

Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: A New Cause of Hypertension

Current Hypertension Reviews, Vol. 3, Iss. 2, 2007-05 ,pp. : 149-155

Bentham Science Publishers

Access to resources Recommend Favorite

Suramin is a Potent Inhibitor of Vascular Endothelial Growth Factor. A Contribution to the Molecular Basis of its Antiangiogenic Action

By Waltenberger J. Mayr U. Frank H. Hombach V.

Journal of Molecular and Cellular Cardiology, Vol. 28, Iss. 7, 1996-07 ,pp. : 1523-1529

Academic Press

Access to resources Recommend Favorite

Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: Effect on human microvascular endothelial cell proliferation and angiogenesis

By Gupta K.

Angiogenesis, Vol. 3, Iss. 2, 1999-01 ,pp. : 147-158

Springer Publishing Company

Access to resources Recommend Favorite